Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial
2017 ESMO CongressBernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).
Related Videos
Caroline Robert, MD, PhD, on Melanoma: Treatment With Nivolumab and Ipilimumab
Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolu...
Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed p...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locall...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negati...
Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update
Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.
